196 related articles for article (PubMed ID: 37490805)
21. An
Zmuda F; Blair A; Liuzzi MC; Malviya G; Chalmers AJ; Lewis D; Sutherland A; Pimlott SL
J Med Chem; 2018 May; 61(9):4103-4114. PubMed ID: 29630818
[TBL] [Abstract][Full Text] [Related]
22. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
[TBL] [Abstract][Full Text] [Related]
23. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
24. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
25. First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET.
Krebs S; Veach DR; Carter LM; Grkovski M; Fornier M; Mauro MJ; Voss MH; Danila DC; Burnazi E; Null M; Staton K; Pressl C; Beattie BJ; Zanzonico P; Weber WA; Lyashchenko SK; Lewis JS; Larson SM; Dunphy MPS
J Nucl Med; 2020 Nov; 61(11):1580-1587. PubMed ID: 32169913
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG
J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448
[TBL] [Abstract][Full Text] [Related]
27. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Michel LS; Dyroff S; Brooks FJ; Spayd KJ; Lim S; Engle JT; Phillips S; Tan B; Wang-Gillam A; Bognar C; Chu W; Zhou D; Mach RH; Laforest R; Chen DL
Radiology; 2017 Feb; 282(2):453-463. PubMed ID: 27841728
[TBL] [Abstract][Full Text] [Related]
28. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
[TBL] [Abstract][Full Text] [Related]
29. High in-vivo stability in preclinical and first-in-human experiments with [
Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
[TBL] [Abstract][Full Text] [Related]
30. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation and Pilot Clinical Study of Al
Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
[TBL] [Abstract][Full Text] [Related]
32. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
33. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
34. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
35. Improved production of
Ellison PA; Olson AP; Barnhart TE; Hoffman SLV; Reilly SW; Makvandi M; Bartels JL; Murali D; DeJesus OT; Lapi SE; Bednarz B; Nickles RJ; Mach RH; Engle JW
Nucl Med Biol; 2020; 80-81():32-36. PubMed ID: 31575457
[TBL] [Abstract][Full Text] [Related]
36. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Evaluation of
Banerjee SR; Minn I; Kumar V; Josefsson A; Lisok A; Brummet M; Chen J; Kiess AP; Baidoo K; Brayton C; Mease RC; Brechbiel M; Sgouros G; Hobbs RF; Pomper MG
J Nucl Med; 2020 Jan; 61(1):80-88. PubMed ID: 31253744
[TBL] [Abstract][Full Text] [Related]
38. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
[TBL] [Abstract][Full Text] [Related]
40. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
